Health Canada consultation on proposed vaping products promotion regulations
https://policybase.cma.ca/link/policy14128

POLICY TYPE  Response to consultation  
DATE  2020-01-20  
TOPICS  Health care and patient safety  
Population health, health equity, public health

Documents
Health Canada consultation on vaping products labelling and packaging regulations
https://policybase.cma.ca/link/policy14124

POLICY TYPE: Response to consultation
DATE: 2019-09-05
TOPICS: Health care and patient safety
Population health, health equity, public health

Documents
Health Canada consultation on potential market for cannabis health products that would not require practitioner oversight
https://policybase.cma.ca/link/policy14125

POLICY TYPE  Response to consultation
DATE  2019-09-03
TOPICS  Health care and patient safety
Population health, health equity, public health

Documents
Health Canada consultation on the impact of vaping products advertising on youth and non-users of tobacco products
https://policybase.cma.ca/link/policy14022

POLICY TYPE  Response to consultation
DATE  2019-03-22
TOPICS  Health care and patient safety
         Population health, health equity, public health

Documents
Health Canada’s consultation on new health-related labelling for tobacco products
https://policybase.cma.ca/link/policy13939

POLICY TYPE          Response to consultation
DATE                 2018-12-14
TOPICS               Health care and patient safety
Population health, health equity, public health

Documents

CMA response:
HEALTH CANADA’S
CONSULTATION ON NEW HEALTH-RELATED LABELLING FOR
TOBACCO PRODUCTS

2nd December 13, 2018
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE  Response to consultation
DATE  2018-10-02
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE Response to consultation
DATE 2018-09-06
TOPICS Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE  Response to consultation
DATE     2018-04-23
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the renewal of Federal Tobacco Control Strategy

https://policybase.cma.ca/link/policy13804

POLICY TYPE
Response to consultation

DATE
2017-04-05

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Front-of-package labelling consultation
https://policybase.cma.ca/link/policy13800

POLICY TYPE
Response to consultation

DATE
2016-10-31

TOPICS
Health care and patient safety

Documents
Regulation of Self-Care Products in Canada
https://policybase.cma.ca/link/policy13802

POLICY TYPE
Response to consultation

DATE
2016-10-31

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE  Response to consultation
DATE  2016-08-12
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

August 12, 2016

Dr. Michelle Catanzano
Chemoformics-Pharmaceuticals Reporting Office
Canadian Medical Association
900 York Street, Suite 700
Ottawa, ON K1N 7N5

Dear Dr. Catanzano,

I am please to receive the consultation on Health Canada’s Consultation on “Plain and Standardized Packaging.”

Canada’s pharmaceuticals have been noted for the lack of standardization of packaging which is a matter for concern. The CMA stand on the role of patients knowing the type of patients to ensure that they are able to make informed decisions when choosing a medication.

The CMA has found that the plain and standardized packaging is a mixed blessing with the majority of patients preferring the plain packaging. This is because it is easier to read and understand.

In response to the consultation, I would like to make the following points:

1. The CMA recommends that the plain and standardized packaging should be mandatory for all medications.
2. The CMA recommends that the packaging should be designed to be easy to read and understand.
3. The CMA recommends that the packaging should be easy to open and close.
4. The CMA recommends that the packaging should be easy to carry and transport.

I would like to know what you think of this recommendation. I would be grateful for your comments.

Sincerely,

Dr. John Doe
Canadian Medical Association
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

**POLICY TYPE**  
Response to consultation

**DATE**  
2016-01-20

**TOPICS**  
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

**Documents**
Tamper Resistance under the Controlled Drugs and Substances Act

https://policybase.cma.ca/link/policy11295

POLICY TYPE  Response to consultation
DATE  2014-08-26
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents